GlassScriptPhysician profile
Pankaj Shukla
NPI 1114937190
$6,460.29
in general payments reported to CMS, 2019-2025
45 companies · $724 in 2025
The $724 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $975 · 2021: $1,098 · 2022: $1,150 · 2023: $1,090 · 2024: $677 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,448 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,448.34 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,028.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $882.78 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $777.72 | 2019-2025 | Repatha, Otezla, Otezla |
| Nestle Healthcare Nutrition INC. | $299.63 | 2020-2023 | |
| Amarin Pharma, INC. | $289.02 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $246.00 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $235.47 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.85 | 2019-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $200.81 | 2020-2023 | Verquvo, Steglatro, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.01 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $195.60 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Scilex Pharmaceuticals INC. | $183.88 | 2019-2024 | |
| Mannkind Corporation | $172.37 | 2020-2025 | Afrezza |
| Abbvie INC. | $155.42 | 2021-2023 | Ubrelvy, Qulipta, Synthroid |
| Kowa Pharmaceuticals America, INC. | $145.59 | 2019-2025 | Zoryve |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $138.23 | 2019-2024 | Jardiance, Mounjaro |
| Sanofi-Aventis U.S. LLC | $113.38 | 2019-2023 | |
| Pfizer INC. | $95.99 | 2019-2020 | |
| Dexcom, INC. | $74.11 | 2021-2022 | |
| Ardelyx, INC. | $67.57 | 2024-2025 | Ibsrela |
| Mylan Specialty L.P. | $61.37 | 2021-2024 | Yupelri |
| Nevro Corp. | $54.41 | 2023 | Senza |
| Phathom Pharmaceuticals, INC. | $54.32 | 2024-2025 | Voquezna |
| Abbott Laboratories | $54.07 | 2022-2025 | Freestyle Libre 3 |
| Allergan, INC. | $46.39 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $44.25 | 2023-2025 | Gemtesa |
| Horizon Therapeutics Plc | $41.62 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $36.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $35.81 | 2020 | |
| Medtronic Vascular, INC. | $32.48 | 2019 | |
| Shield Therapeutics INC | $32.33 | 2024-2025 | |
| Pulmonx Corporation | $32.30 | 2022 | |
| Amneal Pharmaceuticals LLC | $23.08 | 2023 | Lyvispah |
| Alexion Pharmaceuticals, INC. | $21.57 | 2024 | Ultomiris |
| Teleflex LLC | $18.78 | 2025 | Barrigel |
| E.R. Squibb & Sons, L.L.C. | $18.32 | 2023 | Eliquis |
| Insulet Corporation | $18.01 | 2021 | |
| Exact Sciences Corporation | $17.65 | 2023 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $16.71 | 2024 | Collagenase Santyl |
| Biohaven Pharmaceuticals, INC. | $16.53 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.43 | 2019 | |
| Depuy Synthes Sales INC. | $16.04 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.91 | 2024 | |
| Seqirus USA INC | $14.37 | 2025 | Flucelvax, Fluad |
| Avanir Pharmaceuticals, INC. | $13.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pankaj Shukla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.